Reporter brief
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This is a phase II dose-finding study with no efficacy results reported, so no claims can be made about whether fisetin actually reduces sepsis progression or organ failure
- The adaptive allocation design and focus on identifying an efficacious dose means this trial is not powered to definitively establish clinical benefit—that is reserved for a future phase III trial
- Sample size and effect sizes are not reported, preventing assessment of statistical power or the magnitude of any observed differences
Study design and sample
Rct; Human.
Older patients with sepsis
- Design
- Rct
- Sample
- —
- Journal
- University of Minnesota
- Published
- Sep 1, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.